TLR7 and neoplasm: Immune-stimulating antibody conjugates (ISACs, Figure 1A) are based on tumor-targeting monoclonal antibodies (mAbs) functionalized with small molecule agonists of Toll-Like Receptors 7 and 8 (TLR7/8) such as imidazoquinoline derivatives (IMDs) (Bhagchandani et al., 2021).